Immunovant, Inc. (IMVT) Stock: Price, Forecast & Analyst Target
Immunovant, Inc. (IMVT) — MoonshotScore 24/100 (Weak band), calculated Oct 4, 2026. Price $33.62 (-0.09%), as of the Oct 2, 2026 trading session; market cap $6.94B. Expected results Nov 9, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 8.70× (market value Oct 2, 2026; cash Jun 30, 2026) · expected results Nov 9, 2026
Immunovant, Inc. · IMVT · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Immunovant develops antibody therapies for autoimmune disease, led by batoclimab, which blocks FcRn to alter a disease-relevant immune mechanism. Its value depends on whether clinical progress can justify heavy research spending before the cash runway becomes restrictive.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Immunovant (IMVT)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — bottom-tier quality underneath; a move to treat with suspicion, not chase. Business Quality: Thin; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Fading; Momentum: Surging.
- quarterly revenue $7M (Q1 FY2027, quarter ended Jun 2026)
- EPS beat 3 of 8
- Altman Z 31.39 · Piotroski F 3
Holding back: weak fundamentals, soft growth
Helping: balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 24 | Weak | |
| 24 | Weak | |
| 24 | Weak | |
| 24 | Weak | |
| 24 | Weak | |
| 24 | Weak |
The score was 24 in the stored Oct 3, 2026 snapshot and remains 24 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Valuation -1 and Momentum +1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $33.62 |
| Change on the day | -0.09% |
| 52-week range | $15.95–$45.42 |
| Market capitalisation | $6.94B |
| Price / earnings (trailing) | -10.36 |
| Shares traded on the day | 1.02M |
| Beta (volatility vs the S&P 500) | 0.81 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for Immunovant (IMVT): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 27, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 27, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 27, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the IMVT film — every key number, told as a short cinematic story
~2 min · open the film
What is Immunovant (IMVT), and what does it report?
Short answer · as of
This is a clinical-development biotechnology company, not a commercial drugmaker with recurring product demand. Batoclimab is the primary program described, with development spanning myasthenia gravis, thyroid eye disease and warm autoimmune hemolytic anemia.
Research dated 2026-09-13.
This is a clinical-development biotechnology company, not a commercial drugmaker with recurring product demand. Batoclimab is the primary program described, with development spanning myasthenia gravis, thyroid eye disease and warm autoimmune hemolytic anemia.
Reported losses and cash outflows therefore measure the cost of advancing the pipeline more directly than commercial performance. A modest revenue entry appeared in the latest quarter after annual periods without revenue, but that change alone does not establish a recurring product-sales business.
What do the latest results show for Immunovant (IMVT)?
Short answer · as of
The most recent reported quarter, Q1 FY2027, carried revenue of $7M.
Research dated 2026-09-13.
The latest results show research spending holding near its newly elevated level, while operating and net losses widened from the preceding period. Operating cash use also increased, confirming that the heavier development expense is translating into a faster drain on liquidity.
Reported revenue matched the corresponding estimate, yet the loss was worse than expected. The financial record supports the spending increase and wider loss, but it does not identify the revenue source or attribute the change to a management explanation.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $7.09M Jun 30, 2026
- Latest quarter · R&D
- $142.63M Jun 30, 2026
- Latest quarter · SG&A
- $17.69M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$153.23M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $7.09M | $142.63M | $17.69M | −$153.23M |
| Mar 31, 2026 | $0.00 | $142.29M | $17.27M | −$159.55M |
| Dec 31, 2025 | $0.00 | $98.92M | $15.44M | −$114.36M |
| Sep 30, 2025 | $0.00 | $114.25M | $17.51M | −$131.76M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $7.09M Aug 6, 2026
- Latest report · revenue estimate
- $7.09M Aug 6, 2026
- Latest report · revenue vs estimate
- In line Aug 6, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 6, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 6, 2026 | $7.09M | $7.09M | −$0.7500 | −$0.6289 |
| May 20, 2026 | Not available | Not available | −$0.7300 | −$0.5920 |
| Feb 6, 2026 | Not available | $6.00M | −$0.6100 | −$0.7200 |
| Nov 10, 2025 | Not available | Not available | −$0.7300 | −$0.7200 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2027 | $7M | -$153M | -$0.75 (diluted) |
| Q4 FY2026 | $0 | -$148M | -$0.73 (diluted) |
| Q3 FY2026 | $0 | -$111M | -$0.61 (diluted) |
| Q2 FY2026 | $0 | -$127M | -$0.73 (diluted) |
What are the financial strengths and risks for Immunovant (IMVT)?
Short answer
Cash and short-term investments were $797.80M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$124.40M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Immunovant carries no reported debt and holds cash and short-term investments well above total liabilities. That gives the clinical program meaningful financial flexibility without near-term debt service competing for research capital.
The protection is finite. Operations consistently consume cash, the latest outflow accelerated, and the cash balance has declined across recent periods following an earlier increase. At the recent spending pace, funding risk can return before a long clinical and commercialization timetable is complete.
Market value also stands far above net cash, so the equity case reflects substantial value assigned to future program outcomes rather than balance-sheet assets. Weak clinical evidence, delays or continued spending without corresponding progress would pressure that premise.
Data-derived red flags
- Negative return on equity (-68.2%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$124.40M Jun 30, 2026
- Previous quarter · operating cash flow
- −$95.06M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$124.40M | $0.00 |
| Mar 31, 2026 | −$95.06M | −$10,000 |
| Dec 31, 2025 | −$92.32M | $0.00 |
| Sep 30, 2025 | −$102.51M | $0.00 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Immunovant (IMVT)?
Short answer · as of
The next earnings report is expected on Nov 9, 2026.
Research dated 2026-09-13.
The next earnings release should be read for recurrence of the recent revenue entry, movement in research expense and the pace of operating cash use. Repeating revenue without clarification of its source would still provide limited evidence about commercial demand, while another rise in burn would shorten the financial margin for clinical execution.
Longer-range estimates assume revenue expands substantially before earnings turn positive. Progress that broadens the expected revenue base while containing research and administrative costs would support that path; estimate slippage alongside falling cash would weaken it.
How does Immunovant compare with its peers?
Short answer
Immunovant's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Immunovant differs from diversified biotechnology companies because its business is centered on a clinical antibody program aimed at FcRn rather than an established portfolio of marketed products. Research expense dominates the operating structure, while capital expenditure is negligible, making clinical development the principal use of cash.
That structure concentrates both upside and failure risk in evidence generated by the autoimmune pipeline. Comparisons based on sales multiples or gross margin offer little insight while reported revenue remains minimal and recurring product economics are unproven.
| Company | Price | Market value | Score |
|---|---|---|---|
| $322.28 Oct 2, 2026 | $9.54B | 97 5-pillar Oct 4, 2026 | |
| $302.96 Oct 2, 2026 | $6.07B | 96 5-pillar Oct 4, 2026 | |
| $28.30 Oct 2, 2026 | $8.00B | 89 5-pillar Oct 4, 2026 | |
| $19.95 Oct 2, 2026 | $3.42B | 76 5-pillar Oct 4, 2026 | |
| $140.06 Oct 2, 2026 | $9.01B | 76 5-pillar Oct 4, 2026 | |
| $159.56 Oct 2, 2026 | $6.40B | 69 5-pillar Oct 4, 2026 | |
| $84.52 Oct 2, 2026 | $5.10B | 68 5-pillar Oct 4, 2026 | |
| $54.29 Oct 2, 2026 | $8.31B | 65 5-pillar Oct 4, 2026 | |
| $41.75 Oct 2, 2026 | $7.00B | 64 5-pillar Oct 4, 2026 | |
| $116.76 Oct 2, 2026 | $4.88B | 64 5-pillar Oct 4, 2026 | |
| $14.74 Oct 2, 2026 | $5.12B | 62 5-pillar Oct 4, 2026 | |
| $295.51 Oct 2, 2026 | $8.24B | 58 5-pillar Oct 4, 2026 | |
| Immunovant (IMVT) — this page | $33.62 | $6.94B | 24 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $40.00 – $40.00
- Consensus target
- $40.00
- Median target
- $40.00
Consensus record · Captured .
Measured against a quoted price of $33.62 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 23, 2026
- Transactions
- 63
- Identified insiders
- 8
- Purchases
- 0
- Sales
- 38
- Other transactions
- 25
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 54.0% Period end Jun 30, 2026
- Previous quarter · ownership
- 54.3% Prior to period end Jun 30, 2026
- Reporting holders
- 240 Period end Jun 30, 2026
- Previous quarter · holders
- 227 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Fmr LLC | 16,186,469 |
| Deep Track Capital, LP | 9,341,151 |
| Blackrock, INC. | 7,180,897 |
| Farallon Capital Management LLC | 5,805,000 |
| Baker Bros. Advisors LP | 5,435,220 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Immunovant (IMVT)?
Common Questions About IMVT (Healthcare)
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is Immunovant’s batoclimab designed to do?
Batoclimab is a fully human monoclonal antibody designed to target and block FcRn, a mechanism implicated in autoimmune disease. Its development includes myasthenia gravis, thyroid eye disease and warm autoimmune hemolytic anemia.
Does Immunovant’s reported revenue mean batoclimab is commercial?
Immunovant remains a clinical-development company, while the latest quarter contains a modest revenue entry after annual periods with none. That entry does not by itself demonstrate recurring batoclimab product sales.
Can Immunovant fund batoclimab development from operating cash?
Operations consume cash rather than generate it, so development is funded from existing liquidity and any future financing or other capital sources. The debt-free balance sheet provides room, but the recent burn rate leaves a finite runway.
How concentrated is Immunovant’s spending on its autoimmune pipeline?
Research expense is the dominant reported operating cost and has risen materially across annual periods. The latest quarterly pattern shows that elevated research commitment continuing while administrative expense remains much smaller.
What is the IMVT stock price today?
The last price recorded on this page for Immunovant, Inc. (IMVT) is $33.62, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the IMVT price target?
The analyst consensus price target for Immunovant, Inc. (IMVT) is $40.00 (range $40.00 to $40.00, median $40.00), per FMP data captured Oct 4, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (77 figures)
The 77 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | Durham, NC | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "1000 Park Forty Plaza, Durham, NY, 27713, US". The FMP company description names New York, New York as the headquarters; this page uses the address in this row. |
FMP — 68 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 9, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $33.62 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T18:14:46.248Z. | |
px.change | Change on the day | -0.09% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $6.94B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:01.000Z. Captured from FMP at 2026-10-04T18:14:45.128Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.03 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q1 FY2027 | $7M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $15.95–$45.42 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | -10.36 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.02M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.81 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Eric Venker | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 315 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2022 through FY2026: FY2022 revenue $0.00, net result −$156.73M; FY2023 revenue $0.00, net result −$210.96M; FY2024 revenue $0.00, net result −$259.34M; FY2025 revenue $0.00, net result −$413.84M; FY2026 revenue $0.00, net result −$505.61M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.gross_margin | Gross margin (trailing twelve months) | 97.1% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $7.09M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $142.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $17.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$153.23M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $142.29M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $17.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$159.55M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $98.92M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $15.44M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$114.36M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $114.25M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $17.51M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$131.76M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-06.revenue_actual | Revenue · reported — report date 2026-08-06 | $7.09M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.revenue_estimated | Revenue · estimate — report date 2026-08-06 | $7.09M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_actual | EPS · reported — report date 2026-08-06 | −$0.7500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-06.eps_estimated | EPS · estimate — report date 2026-08-06 | −$0.6289 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-20.eps_actual | EPS · reported — report date 2026-05-20 | −$0.7300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-20.eps_estimated | EPS · estimate — report date 2026-05-20 | −$0.5920 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-06.revenue_estimated | Revenue · estimate — report date 2026-02-06 | $6.00M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-06.eps_actual | EPS · reported — report date 2026-02-06 | −$0.6100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-06.eps_estimated | EPS · estimate — report date 2026-02-06 | −$0.7200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-10.eps_actual | EPS · reported — report date 2025-11-10 | −$0.7300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-10.eps_estimated | EPS · estimate — report date 2025-11-10 | −$0.7200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q1 FY2027 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $797.80M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$124.40M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 9.40× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$124.40M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$95.06M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$10,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$92.32M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$102.51M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | $0.00 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $40.00 – $40.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $40.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $40.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 4, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 63 transactions · 0 purchases, 38 sales, 25 other transactions · 8 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Sep 23, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 54.0% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 54.3% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 240 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 227 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Fmr LLC — shares in provider snapshot | 16,186,469 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Deep Track Capital, LP — shares in provider snapshot | 9,341,151 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Blackrock, INC. — shares in provider snapshot | 7,180,897 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Farallon Capital Management LLC — shares in provider snapshot | 5,805,000 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Baker Bros. Advisors LP — shares in provider snapshot | 5,435,220 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 3 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-02 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 31.39 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -68.2% · ROA -52.8% · current ratio 9.09 · earnings yield -6.4% · free-cash-flow yield -5.1% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 8.70× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $797.80M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-02. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-06.revenue_actual.comparison | Latest report · revenue vs estimate | In line | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($7.09M) with the recorded estimate ($7.09M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-06.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.7500) with the recorded estimate (−$0.6289) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 24 of 100 · Weak · pillars 20 / 84 / 37 / 21 / 83 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 24 (stored snapshot Oct 3, 2026) → 24 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-06. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-06.revenue_actual,earn.history.depth.2026-08-06.revenue_estimated,earn.history.depth.2026-08-06.revenue_actual.comparison,earn.history.depth.2026-08-06.eps_actual.comparison,earn.history.depth.2026-08-06.eps_actual,earn.history.depth.2026-08-06.eps_estimated,earn.history.depth.2026-05-20.eps_actual,earn.history.depth.2026-05-20.eps_estimated,earn.history.depth.2026-02-06.revenue_estimated,earn.history.depth.2026-02-06.eps_actual,earn.history.depth.2026-02-06.eps_estimated,earn.history.depth.2025-11-10.eps_actual,earn.history.depth.2025-11-10.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | Immunovant, Inc. | 2026-05-20 | OFFICIAL | SEC EDGAR — 10-K filed 2026-05-20 |
| Business description | Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2026-03-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Cash runway cross-check (ours) | Years: 1.9; Method: cash and short-term investments of $797.8M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($416M per year); Reaches: 2028-05; Cash basis: cash and short-term investments; Cash: $797.80M; Annualized cash use: $416.00M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-06 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-08-06 | OFFICIAL | SEC EDGAR filer submissions | |
| Cash, investments and debt | Total debt: $0; Liquidity basis: cash and short-term investments; Total liabilities: $117.10M; Cash and short-term investments: $797.80M; Cash and investments: $797.80M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $797.80M; Cash and short-term investments: $797.80M; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $797.80M; Total debt: $0; Cash and investments: $797.80M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Next earnings report | Date: 2026-11-09; EPS estimate: -$0.73 per share; Revenue estimate: $7.09M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Trailing twelve-month ratio set | Quick ratio: 7.27; Current ratio: 7.27; Gross margin: 97.1%; Return on assets: -63.1%; Return on equity: -69.6% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
Data provided for informational purposes only.